Lipocine Announces Presentations at the 21st Annual Fall Meeting of the Sexual Medicine Society of North America

SALT LAKE CITY, Oct. 14, 2020 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it will present results from studies suggesting that low testosterone levels may play an important role on the clinical outcomes of COVID-19 in men as well as the safety and efficacy of TLANDO™, an oral testosterone replacement therapy without a dose titration requirement, at the 21st Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (“SMSNA”). Lipocine will outline the possible mechanisms and clinical evidence that suggests men with low testosterone have poor COVID-19 outcomes, and the rationale of using an oral testosterone therapy for men with COVID-19. Results from the previously completed dose validation (“DV”) study of a fixed dose TLANDO in hypogonadal males will also be presented at the meeting.  The presentations will take place virtually on November 9, 2020

Read More

The Law Offices of Frank R. Cruz Announces Investigation of Loop Industries, Inc. (LOOP) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Loop Industries, Inc. (“Loop” or the “Company”) (NASDAQ: LOOP) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On October 13, 2020, Hindenburg Research published a report alleging, among other things, that “[a] former Loop employee told us that Loop’s scientists, under pressure from CEO Daniel Solomita, were tacitly encouraged to lie about the results of the company’s process internally. We have obtained internal documents and photographs to support their claims.” The report also stated that “Loop’s previous claims of breaking PET down to its base chemicals at a recovery rate of 100% were ‘technically and industrially impossible,’” according to a former employee. Moreover, the report alleged that “Executives from a division of key partner Thyssenkrupp, who Loop entered into a ‘global

Read More

The Law Offices of Frank R. Cruz Announces Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

In June 2019, the Company launched a dose-escalation Phase 1/2 clinical trial for HMI-102, its lead product candidate for the treatment of phenylketonuria. Homology “reported encouraging safety and efficacy data from the dose-escalation portion of the trial” and claimed that the data showed HMI-102 “produced a sustained reduction in phenylalanine (Phe).”

Then, on July 21, 2020, Mariner Research published a report, alleging that the Company’s comments “conveniently ignor[ed] the implications to efficacy and the business.” Citing data from a mouse study, the Phase 1/2 trial, and a key patient’s Facebook posts, the report concluded that HMI-102 “therapy is showing zero efficacy even for a

Read More

Government announces new coronavirus lockdown rules

boris johnsonParliamentlive.tv

Boris Johnson made the announcement in the House of Commons earlier today

Prime Minister Boris Johnson has announced a new strategy for dealing with Covid-19 in different parts of England.

The new system places different areas in England into three tiers – areas with more cases will face further rules.

The new rules come into effect from Wednesday, with places like Liverpool and nearby areas facing the biggest changes to reduce the risk of catching the virus.

For the people living there, they won’t be allowed to mix with anyone from another household indoors or outdoors.

Leisure centres, pubs and bars have been told to close in the region.

Why is this happening?

Liverpool-high-streetGetty Images

The coronavirus infection rate is increasing at different rates in different parts of the UK.

Liverpool and surrounding areas have the some of the highest infection rates of coronavirus. Liverpool recorded 600 cases per

Read More

KAHR Announces Oral Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting

JERUSALEM, Oct. 12, 2020 /PRNewswire/ — KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced that an abstract reporting preclinical data for DSP107, a second generation CD47x41BB targeting compound for the treatment of solid tumors and hematological malignancies, has been accepted for an oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually from December 5-8, 2020.

“The ASH Annual Meeting will be an important opportunity to present mechanistic studies and extensive in vitro and in vivo results from our novel CD47x41BB clinical stage drug candidate,” said Yaron Pereg, Ph.D., Chief Executive Officer of KAHR. “We look forward to advancing the clinical development of this novel therapy.”

The following abstract will be posted on the ASH website on November 5, 2020, at 9:00 a.m. ET:

Title: DSP107, a Novel Bi-Functional Fusion Protein That Combines Inhibition

Read More

Tricida Announces Twelve Data Presentations on Veverimer and Metabolic Acidosis to be Given at the Virtual American Society of Nephrology Kidney Week 2020

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it has authored or sponsored 12 presentations at the upcoming American Society of Nephrology (ASN) Kidney Week 2020 being held virtually October 22-25, 2020. Data to be presented at multiple sessions at the meeting will expand the breadth of information about the implications of metabolic acidosis and CKD. All Tricida presentations will be available on Thursday, October 22, 2020 at 10:00am ET. Session and presentation titles are listed below:

Session Title: CKD Risk Factors: Diet, Environment, Lifestyle

Title:

Relationship Between Metabolic Acidosis and Chronic Kidney Disease Progression is Evident Across United States Racial and Ethnic Groups

Author:

N. Tangri et al.

ePoster #:

PO0468

 

 

Title:

Read More

The Law Offices of Frank R. Cruz Announces Investigation of Liberty Oilfield Services Inc. (LBRT) on Behalf of Investors

The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Liberty Oilfield Services Inc. (“Liberty” or “the Company”) (NYSE: LBRT) concerning whether the board breached its fiduciary duties to shareholders.

If you are a shareholder, click here to participate.

On February 5, 2020, after the market closed, Liberty issued a press release announcing its financial and operations results for fourth quarter and full year 2019. Therein, Liberty reported full year adjusted EBITDA of $277 million, or a 37% decline over the prior year, and diluted earnings per share of $0.53, which fell significantly short of analyst forecasts.

On this news, Liberty’s stock price fell $1.07, or over 12%, to close at $7.80 per share on February 6, 2020, thereby injuring investors.

Our investigation concerns whether the Company’s board of directors breached its fiduciary duties to shareholders and/or grossly mismanaged the Company in connection

Read More

The Law Offices of Frank R. Cruz Announces Investigation of Amyris, Inc. (AMRS) on Behalf of Investors

The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Amyris, Inc (“Amyris” or the “Company”) (NASDAQ: AMRS) concerning whether the board breached its fiduciary duties to shareholders.

If you are a shareholder, click here to participate.

On March 19, 2019, Amyris announced was unable to file its annual report for fiscal year ended December 31, 2018 on time due to “the significant time and resources that were devoted to the accounting for and disclosure of the significant transactions with Koninklijke DSM N.V. that closed in November 2018.” The Company also disclosed that it was “in the process of completing its evaluation of internal control over financial reporting.”

On this news, Amyris’ share price fell $0.78, or nearly 20% to close at $3.10 per share on March 20, 2019, thereby injuring investors.

Our investigation concerns whether the Company’s board of directors breached its

Read More

The American Society of Transplantation Announces New Living Donor Circle of Excellence Program

Fourteen large employers join Circle of Excellence to increase living organ donation

MOUNT LAUREL, N.J., Oct. 7, 2020 /CNW/ — The American Society of Transplantation (AST) is proud to announce its new Living Donor Circle of Excellence program. “The Circle” celebrates employers who implement internal policies that provide salary support to their employees who choose to be a living organ donor.

Today, more than 100,000 patients are waiting for a life-saving kidney or liver transplant. Of the transplants performed in 2019, living donors accounted for 30% of kidney transplants and 6% of liver transplants. Financial disincentives are a barrier for many potential living organ donors. Living organ donation typically includes a four- to six-week recovery period and many will use their vacation time or take unpaid absences during this period to donate.

“With fewer than four living donors per 100,000 employed persons, most companies will only rarely support a

Read More

The Law Offices of Frank R. Cruz Announces Investigation of Aurora Cannabis, Inc. (ACB) on Behalf of Investors

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz announces an investigation of Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On September 8, 2020, the Company announced that it expected to record up to $1.8 billion in goodwill impairment charges in fourth quarter 2020. According to Aurora’s press release, these charges included “up to $90 million” in fixed asset impairment charges “due to production facility rationalization, and a charge of approximately $140 million in the carrying value of certain inventory, predominantly trim, in order to align inventory on hand with near term expectations for demand.”

On this news, the Company’s stock price fell $0.99 per share, or more than 11%, to close at

Read More